Cargando…

Clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound

BACKGROUND: The purpose of these clinical studies was to validate a Tissue Change Monitoring (TCM) algorithm in vivo. TCM is a quantitative tool for the real-time assessment of HIFU dose. TCM provides quantitative analysis of the backscatter pulse echo signals (pre and immediately post HIFU) for eac...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanghvi, Narendra T., Chen, Wo-Hsing, Carlson, Roy, Weis, Clint, Seip, Ralf, Uchida, Toyoaki, Marberger, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598037/
https://www.ncbi.nlm.nih.gov/pubmed/28924476
http://dx.doi.org/10.1186/s40349-017-0102-2
_version_ 1783263819591581696
author Sanghvi, Narendra T.
Chen, Wo-Hsing
Carlson, Roy
Weis, Clint
Seip, Ralf
Uchida, Toyoaki
Marberger, Michael
author_facet Sanghvi, Narendra T.
Chen, Wo-Hsing
Carlson, Roy
Weis, Clint
Seip, Ralf
Uchida, Toyoaki
Marberger, Michael
author_sort Sanghvi, Narendra T.
collection PubMed
description BACKGROUND: The purpose of these clinical studies was to validate a Tissue Change Monitoring (TCM) algorithm in vivo. TCM is a quantitative tool for the real-time assessment of HIFU dose. TCM provides quantitative analysis of the backscatter pulse echo signals (pre and immediately post HIFU) for each individual ablative site, using ultrasonic tissue characterization as a surrogate for monitoring tissue temperature. Real-time analysis generates an energy difference parameter (ΔE in dB) that is proportional to tissue temperature. METHODS: Post in vitro studies, two clinical studies were conducted to validate the TCM algorithm on the Sonablate® device. Studies enrolled histologically confirmed, organ confined prostate cancer patients. The first clinical study was conducted in two phases for whole gland ablation. First eight patients’ data were used to measure the algorithm performance followed by 89 additional patients for long term outcome. The second clinical study enrolled five patients; four patients with focal cancer had hemi-ablation only and one had whole gland ablation. Four 3 Fr. needles containing three thermocouples each were placed transperineally in the prostate to record tissue temperatures in the focal zone, posterior to the focal zone and on the lateral gland where no HIFU was applied. Tissue temperatures from the focal zone were correlated to the ΔE parameter. RESULTS: In the first clinical study, the average TCM rate was 86%. Pre and 6 months post HIFU, median PSA was 7.64 and 0.025 ng/ml respectively and 97% patients had negative biopsy. For the second clinical study, the measured prostate tissue temperatures (Average, Max, and Min) in the ablation zones were 84°, 114° and 60 °C and the corresponding ΔE (dB/10) parameters were 1.05, 2.6 and 0.4 resulting in 83% of temperatures in the range of 75°-100 °C and 17% in the 60°-74 °C range. Outside the focal zone, the average temperature was 50 °C and in the lateral lobe where no HIFU was applied, peak temperature was 40.7 °C. CONCLUSIONS: The TCM algorithm is able to estimate tissue changes reliably during the HIFU procedure for prostate tissue ablation in real-time and can be used as a guide for HIFU dose delivery and tissue ablation control.
format Online
Article
Text
id pubmed-5598037
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55980372017-09-18 Clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound Sanghvi, Narendra T. Chen, Wo-Hsing Carlson, Roy Weis, Clint Seip, Ralf Uchida, Toyoaki Marberger, Michael J Ther Ultrasound Research BACKGROUND: The purpose of these clinical studies was to validate a Tissue Change Monitoring (TCM) algorithm in vivo. TCM is a quantitative tool for the real-time assessment of HIFU dose. TCM provides quantitative analysis of the backscatter pulse echo signals (pre and immediately post HIFU) for each individual ablative site, using ultrasonic tissue characterization as a surrogate for monitoring tissue temperature. Real-time analysis generates an energy difference parameter (ΔE in dB) that is proportional to tissue temperature. METHODS: Post in vitro studies, two clinical studies were conducted to validate the TCM algorithm on the Sonablate® device. Studies enrolled histologically confirmed, organ confined prostate cancer patients. The first clinical study was conducted in two phases for whole gland ablation. First eight patients’ data were used to measure the algorithm performance followed by 89 additional patients for long term outcome. The second clinical study enrolled five patients; four patients with focal cancer had hemi-ablation only and one had whole gland ablation. Four 3 Fr. needles containing three thermocouples each were placed transperineally in the prostate to record tissue temperatures in the focal zone, posterior to the focal zone and on the lateral gland where no HIFU was applied. Tissue temperatures from the focal zone were correlated to the ΔE parameter. RESULTS: In the first clinical study, the average TCM rate was 86%. Pre and 6 months post HIFU, median PSA was 7.64 and 0.025 ng/ml respectively and 97% patients had negative biopsy. For the second clinical study, the measured prostate tissue temperatures (Average, Max, and Min) in the ablation zones were 84°, 114° and 60 °C and the corresponding ΔE (dB/10) parameters were 1.05, 2.6 and 0.4 resulting in 83% of temperatures in the range of 75°-100 °C and 17% in the 60°-74 °C range. Outside the focal zone, the average temperature was 50 °C and in the lateral lobe where no HIFU was applied, peak temperature was 40.7 °C. CONCLUSIONS: The TCM algorithm is able to estimate tissue changes reliably during the HIFU procedure for prostate tissue ablation in real-time and can be used as a guide for HIFU dose delivery and tissue ablation control. BioMed Central 2017-09-13 /pmc/articles/PMC5598037/ /pubmed/28924476 http://dx.doi.org/10.1186/s40349-017-0102-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sanghvi, Narendra T.
Chen, Wo-Hsing
Carlson, Roy
Weis, Clint
Seip, Ralf
Uchida, Toyoaki
Marberger, Michael
Clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound
title Clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound
title_full Clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound
title_fullStr Clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound
title_full_unstemmed Clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound
title_short Clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound
title_sort clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598037/
https://www.ncbi.nlm.nih.gov/pubmed/28924476
http://dx.doi.org/10.1186/s40349-017-0102-2
work_keys_str_mv AT sanghvinarendrat clinicalvalidationofrealtimetissuechangemonitoringduringprostatetissueablationwithhighintensityfocusedultrasound
AT chenwohsing clinicalvalidationofrealtimetissuechangemonitoringduringprostatetissueablationwithhighintensityfocusedultrasound
AT carlsonroy clinicalvalidationofrealtimetissuechangemonitoringduringprostatetissueablationwithhighintensityfocusedultrasound
AT weisclint clinicalvalidationofrealtimetissuechangemonitoringduringprostatetissueablationwithhighintensityfocusedultrasound
AT seipralf clinicalvalidationofrealtimetissuechangemonitoringduringprostatetissueablationwithhighintensityfocusedultrasound
AT uchidatoyoaki clinicalvalidationofrealtimetissuechangemonitoringduringprostatetissueablationwithhighintensityfocusedultrasound
AT marbergermichael clinicalvalidationofrealtimetissuechangemonitoringduringprostatetissueablationwithhighintensityfocusedultrasound